| Combination chemotherapy with trastuzumab in early-stage breast cancer: a meta-analysis and Bayesian decision analysis of different treatment regimens. | 2024 | European Review for Medical and Pharmacological Sciences |
| Efficacy and safety of first-line therapy in patients with HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials. | 2024 | Journal of Cancer Research and Clinical Oncology |
| Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis. | 2024 | ESMO Open |
| Incidence of antibody-drug conjugate-related fatigue in patients with breast cancer: A systematic review and meta-analysis. | 2024 | Critical Reviews in Oncology/Hematology |
| The cardioprotective potential of sodium-glucose cotransporter 2-inhibitors in breast cancer therapy-related cardiac dysfunction - A systematic review. | 2024 | Current Problems in Cardiology |
| A systematic review of health-related quality of life in women with HER2-positive metastatic breast cancer treated with trastuzumab. | 2024 | PharmacoEconomics |
| A review regarding the article 'The cardioprotective potential of sodium-glucose cotransporter 2-inhibitors in breast cancer therapy-related cardiac dysfunction-A systematic review'. | 2024 | Current Problems in Cardiology |
| Safety and efficacy of pyrotinib for HER‑2‑positive breast cancer in the neoadjuvant setting: A systematic review and meta‑analysis. | 2024 | Oncology Letters |
| Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis. | 2023 | European Journal of Cancer |
| Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis. | 2023 | Radiotherapy and Oncology |
| Efficacy and safety of antibody-drug conjugates in triple-negative and HER-2 positive breast cancer: A systematic review and meta-analysis of clinical trials. | 2023 | Breast Disease |
| Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis. | 2023 | ESMO Open |
| Efficacy of anti-HER2 drugs in the treatment of patients with HER2-mutated cancers: a systematic review and meta-analysis. | 2023 | Clinical and Experimental Medicine |
| The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review. | 2023 | Annals of Oncology |
| Efficacy and safety of trastuzumab deruxtecan in breast cancer: a systematic review and meta-analysis. | 2023 | Clinical Breast Cancer |
| Racial disparities in treatment-related cardiovascular toxicities amongst women with breast cancer: a scoping review. | 2023 | Journal of Cancer Survivorship |
| ACEI/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis. | 2023 | Heart Failure Reviews |
| Clinical benefit, price, and uptake for cancer biosimilars vs reference drugs in China: a systematic review and meta-analysis. | 2023 | JAMA Network Open |
| Evaluation of HER-2 positive breast cancer treated with dual-targeted treatment of trastuzumab plus pertuzumab. | 2023 | Immunopharmacology and Immunotoxicology |
| Risk prediction models for antineoplastic-associated cardiotoxicity in treatment of breast cancer: A systematic review. | 2023 | American Journal of Health-System Pharmacy |
| The value of neoadjuvant anthracycline-based regimens for HER2-positive breast cancer: a systematic review and meta-analysis including 1366 patients. | 2023 | Clinical Medicine Insights: Oncology |
| A meta-analysis to assess the efficacy of HER2-targeted treatment regimens in her2-positive metastatic colorectal cancer (mCRC). | 2023 | Current Oncology |
| Chemotherapy induced right ventricular cardiomyopathy; a systematic review and meta-analysis. | 2023 | Frontiers in Cardiovascular Medicine |
| Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis. | 2023 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485391/pdf/main.pdf |
| The efficacy and safety of trastuzumab deruxtecan (T-DXd) in HER2-expressing solid tumours: a single-arm meta-analysis. | 2023 | Japanese Journal of Clinical Oncology |
| Cardioprotective agents for the primary prevention of trastuzumab-associated cardiotoxicity: a systematic review and meta-analysis. | 2023 | Pharmaceuticals |
| Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis. | 2023 | Frontiers in Pharmacology |
| Health-related quality of life in Her2-positive early breast cancer woman using trastuzumab: A systematic review and meta-analysis. | 2023 | Frontiers in Pharmacology |
| Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review. | 2023 | Cancer Treatment Reviews |
| Adjuvant treatment with trastuzumab of patients with HER2-positive, T1a-bN0M0 breast tumors: A systematic review and meta-analysis. | 2023 | Critical Reviews in Oncology/Hematology |
| Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis. | 2023 | Clinical & Translational Oncology |
| Neoadjuvant therapy with vs. without anthracyclines for HER2-positive breast cancer: a systematic review and meta-analysis. | 2023 | Annals of Translational Medicine |
| Prognostic value of left ventricular global longitudinal strain on speckle echocardiography for predicting chemotherapy-induced cardiotoxicity in breast cancer patients: A systematic review and meta-analysis. | 2023 | Echocardiography |
| Treatment options for patients with human epidermal growth factor 2-positive breast cancer brain metastases: A systematic review and meta-analysis. | 2023 | Frontiers in Oncology |
| Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. | 2023 | EClinicalMedicine |
| Axillary downstaging and the impact of clinical axillary status on efficacy of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis. | 2023 | Technology in Cancer Research & Treatment |
| Neoadjuvant treatment with HER2-targeted therapies in HER2-positive breast cancer: a systematic review and network meta-analysis. | 2022 | Cancers |
| Effectiveness and cost-effectiveness of trastuzumab emtansine in women with HER2-positive locally advanced or metastatic breast cancer: a systematic review and meta-analysis. | 2022 | Journal of Cancer Research and Therapeutics |
| Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis. | 2022 | Cancers |
| Incidence and risk of severe adverse events associated with trastuzumab emtansine (T-DM1) in the treatment of breast cancer: an up-to-date systematic review and meta-analysis of randomized controlled clinical trials. | 2022 | Expert Review of Clinical Pharmacology |
| T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis. | 2022 | BMC Cancer |
| Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis. | 2022 | Immunopharmacology and Immunotoxicology |
| Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer. | 2022 | Cancer Treatment Reviews |
| The adverse effects of trastuzumab-containing regimes as a therapy in breast cancer: A piggy-back systematic review and meta-analysis. | 2022 | PLoS One |
| Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis. | 2022 | Systematic Reviews |
| Cardiotoxicity in cancer patients treated with chemotherapy: A systematic review. | 2022 | International Journal of Health Sciences |
| Safety of trastuzumab deruxtecan: A meta-analysis and pharmacovigilance study. | 2022 | Journal of Clinical Pharmacy and Therapeutics |
| Efficacy and safety of PI3K/Akt/mTOR inhibitors combined with trastuzumab therapy for HER2-positive breast cancer: a meta-analysis. | 2022 | European Review for Medical and Pharmacological Sciences |
| Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials. | 2022 | Frontiers in Oncology |
| Trastuzumab combined chemotherapy for the treatment of HER2-positive advanced gastric cancer: A systematic review and meta-analysis of randomized controlled trial. | 2022 | Medicine |
| Insights on the molecular targets of cardiotoxicity induced by anticancer drugs: A systematic review based on proteomic findings. | 2022 | Metabolism |
| A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer. | 2022 | European Heart Journal |
| Determining the optimal (neo)adjuvant regimen for human epidermal growth factor receptor 2-positive breast cancer regarding survival outcome: a network meta-analysis. | 2022 | Frontiers in Immunology |
| Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: a systematic review. | 2022 | BMC Cancer |
| Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality. | 2022 | Cancer Treatment Reviews |
| Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials. | 2022 | ESMO Open |
| Efficacy of second-line treatments for patients with advanced human epidermal growth factor receptor 2 positive breast cancer after trastuzumab-based treatment: a systematic review and Bayesian network analysis. | 2021 | Journal of Cancer |
| Assessment of racial differences in the incidence of thrombocytopenia induced by trastuzumab emtansine: a systematic review and meta-analysis. | 2021 | Annals of Translational Medicine |
| Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis. | 2021 | Future Oncology |
| Efficacy and safety of pyrotinib versus T-DM1 in HER2+ metastatic breast cancer patients pre-treated with trastuzumab and a taxane: a Bayesian network meta-analysis. | 2021 | Frontiers in Oncology |
| Prolonged responses with trastuzumab emtasine treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer refractory to trastuzumab and pertuzumab: systematic review of evidence. | 2021 | Clinical Breast Cancer |
| Docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer: a meta-analysis. | 2021 | European Review for Medical and Pharmacological Sciences |
| Treatment outcomes among human epidermal growth factor receptor 2 positive breast cancer patients: A systematic review. | 2021 | Journal of Oncology Pharmacy Practice |
| Efficacy and safety of anti-HER2 agents in combination with chemotherapy for metastatic her2-positive breast cancer patient: a network meta-analysis. | 2021 | Frontiers in Oncology |
| Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. | 2021 | The Lancet Oncology |
| Use of trastuzumab in treating breast cancer during pregnancy: a systematic review and meta-analysis. | 2021 | BMC Women’s Health |
| 6 versus 12 months of adjuvant trastuzumab in HER2+ early breast cancer: A systematic review and meta-analysis. | 2021 | Medicine |
| Methodological quality evaluation of systematic reviews or meta-analysis of trastuzumab-based therapy for breast cancer: A systematic review. | 2021 | Medicine |
| The efficacy and safety of additional anti-HER2-targeting drugs in the treatment of her2-positive advanced breast cancer: a meta-analysis. | 2021 | Anticancer Agents in Medicinal Chemistry |
| Dual HER2 blockade in neoadjuvant treatment of HER2+ breast cancer: a meta-analysis and review. | 2020 | Technology in Cancer Research & Treatment |
| A network meta-analysis on the efficacy of HER2-targeted agents in combination with taxane-containing regimens for treatment of HER2-positive metastatic breast cancer. | 2020 | Breast Cancer |
| Benefits of adjuvant treatment including trastuzumab in HER2-positive pT1a-bN0M0 breast cancer: a systematic review and meta-analysis. | 2020 | Annals of Translational Medicine |
| Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. | 2020 | Journal of Oncology |
| Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis. | 2020 | Breast Cancer Research and Treatment |
| Six months vs. 12 months of adjuvant trastuzumab among women with HER2-positive early-stage breast cancer: a meta-analysis of randomized controlled trials. | 2020 | Frontiers in Oncology |
| Regimens of neo-adjuvant chemotherapy in the treatment of breast cancer: A systematic review & network meta-analysis with PRISMA-NMA compliance. | 2020 | Critical Reviews in Oncology/Hematology |
| Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis. | 2020 | Breast |
| Targeted neoadjuvant therapy in the HER-2-positive breast cancer patients: a systematic review and meta-analysis. | 2019 | OncoTargets and Therapy |
| One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis. | 2019 | Breast Cancer Research and Treatment |
| Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis. | 2019 | Breast Cancer Research and Treatment |
| Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials. | 2019 | Breast Cancer Research and Treatment |
| Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: A meta-analysis of randomized controlled trials. | 2019 | Cancer Treatment Reviews |
| Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. | 2019 | The Lancet Oncology |
| Trastuzumab biosimilar in metastatic breast cancer: Evaluating equivalence with originator using network meta-analysis. | 2019 | International Journal of Clinical Pharmacology and Therapeutics |
| Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer. | 2019 | Medicine |
| Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis. | 2019 | Expert Review of Clinical Pharmacology |
| Effectiveness of Added Targeted Therapies to Neoadjuvant Chemotherapy for Breast Cancer: A Systematic Review and Meta-analysis. | 2019 | Clinical Breast Cancer |
